{
    "clinical_study": {
        "@rank": "8125", 
        "arm_group": {
            "arm_group_label": "Rotigotine", 
            "arm_group_type": "Experimental", 
            "description": "- Titration Period: Weekly titration to the subject's optimal dose of Rotigotine between 2 mg/24 h and 8 mg/24 h. In case of intolerable Adverse Events (AEs) one back-titration is allowed during the Titration Period.\nDuration of the Titration Period: Between 1 week and 5 weeks.\n- Maintenance Period: Starts once subject reached either optimal or maximal dose of Rotigotine. Subjects receive stable dose of Rotigotine throughout the Maintenance Period. No back-titration is allowed during the Maintenance Period.\nDuration of the Maintenance Period: Between 3 weeks and 7 weeks."
        }, 
        "brief_summary": {
            "textblock": "This study is to investigate the safety and efficacy of Rotigotine add-on therapy with low\n      doses of Pramipexole or Ropinirole in patients with advanced-stage Parkinson's Disease (PD)\n      who have insufficient response to L-dopa and low doses dopamine receptor agonists."
        }, 
        "brief_title": "A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": {
                        "@group_id": "B1", 
                        "description": "- Titration Period: Weekly titration to the subject's optimal dose of Rotigotine between 2 mg/24 h and 8 mg/24 h. In case of intolerable Adverse Events (AEs) one back-titration is allowed during the Titration Period.\nDuration of the Titration Period: Between 1 week and 5 weeks.\n- Maintenance Period: Starts once subject reached either optimal or maximal dose of Rotigotine. Subjects receive stable dose of Rotigotine throughout the Maintenance Period. No back-titration is allowed during the Maintenance Period.\nDuration of the Maintenance Period: Between 3 weeks and 7 weeks.\nRotigotine: Application of Rotigotine up to 8 mg/24 h patches for 24 hours.", 
                        "title": "Rotigotine"
                    }
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "90"
                                        }
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@spread": "9.3", 
                                            "@value": "61.3"
                                        }
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "57"
                                            }
                                        }, 
                                        "sub_title": "< 65 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "33"
                                            }
                                        }, 
                                        "sub_title": ">= 65 years"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Age, Customized", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "43"
                                            }
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "47"
                                            }
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "8"
                                            }
                                        }, 
                                        "sub_title": "Taiwan"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "6"
                                            }
                                        }, 
                                        "sub_title": "Malaysia"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "4"
                                            }
                                        }, 
                                        "sub_title": "Singapore"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "6"
                                            }
                                        }, 
                                        "sub_title": "Australia"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "66"
                                            }
                                        }, 
                                        "sub_title": "Korea, Republic of"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Region of Enrollment", 
                            "units": "participants"
                        }
                    ]
                }, 
                "population": "Baseline characteristics refer to the Safety Set. The Safety Set consists of all subjects who had at least one patch application."
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "The CGI Item 4 was used to assess side effects. It ranges from 0 to 4 as follows: 0 = Side effects not assessable\n= No side effects\n= Side effects do not significantly interfere with subject's functioning\n= Side effects significantly interfere with the subject's functioning\n= Side effects outweigh therapeutic efficacy.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "- Titration Period: Weekly titration to the subject's optimal dose of Rotigotine between 2 mg/24 h and 8 mg/24 h. In case of intolerable Adverse Events (AEs) one back-titration is allowed during the Titration Period.\nDuration of the Titration Period: Between 1 week and 5 weeks.\n- Maintenance Period: Starts once subject reached either optimal or maximal dose of Rotigotine. Subjects receive stable dose of Rotigotine throughout the Maintenance Period. No back-titration is allowed during the Maintenance Period.\nDuration of the Maintenance Period: Between 3 weeks and 7 weeks.\nRotigotine: Application of Rotigotine up to 8 mg/24 h patches for 24 hours.", 
                                "title": "Rotigotine"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "89"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "61"
                                                    }
                                                }, 
                                                "sub_title": "CGI Item 4 score of 1"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "22"
                                                    }
                                                }, 
                                                "sub_title": "CGI Item 4 score of 2"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "3"
                                                    }
                                                }, 
                                                "sub_title": "CGI Item 4 score of 3"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "3"
                                                    }
                                                }, 
                                                "sub_title": "CGI Item 4 score of 4"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "6"
                                                    }
                                                }, 
                                                "sub_title": "CGI Item 4 score of 3 or 4"
                                            }
                                        ]
                                    }, 
                                    "description": "The CGI Item 4 was used to assess side effects. It ranges from 0 to 4 as follows: 0 = Side effects not assessable\n= No side effects\n= Side effects do not significantly interfere with subject's functioning\n= Side effects significantly interfere with the subject's functioning\n= Side effects outweigh therapeutic efficacy.", 
                                    "param": "Number", 
                                    "title": "Clinical Global Impression (CGI) Item 4 (Side Effects) at the End of the Treatment Period", 
                                    "units": "participants"
                                }
                            ]
                        }, 
                        "population": "From the 90 subjects in the Safatey Set, 89 are included in the analysis of this outcome measure. Last Observation Carried Forward (LOCF) was used as a method of imputation for missing observations.", 
                        "safety_issue": "No", 
                        "time_frame": "Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)", 
                        "title": "Clinical Global Impression (CGI) Item 4 (Side Effects) at the End of the Treatment Period", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The Unified Parkinson\u00b4s Disease Rating Scale Part III is an accepted and validated scale for the assessment of motor function in Parkinson\u00b4s disease. Each of the 27 sub-items in the UPDRS III is measured on a scale of 0 to 4, where 0 is normal and 4 represents severe abnormalities. The total scores therefore ranges from 0 to 108.\nA negative value in Change from Baseline to Week 8 indicates an improvement in motor functions from Baseline.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "- Titration Period: Weekly titration to the subject's optimal dose of Rotigotine between 2 mg/24 h and 8 mg/24 h. In case of intolerable Adverse Events (AEs) one back-titration is allowed during the Titration Period.\nDuration of the Titration Period: Between 1 week and 5 weeks.\n- Maintenance Period: Starts once subject reached either optimal or maximal dose of Rotigotine. Subjects receive stable dose of Rotigotine throughout the Maintenance Period. No back-titration is allowed during the Maintenance Period.\nDuration of the Maintenance Period: Between 3 weeks and 7 weeks.\nRotigotine: Application of Rotigotine up to 8 mg/24 h patches for 24 hours.", 
                                "title": "Rotigotine"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "89"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "8.3", 
                                                    "@value": "-5.3"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The Unified Parkinson\u00b4s Disease Rating Scale Part III is an accepted and validated scale for the assessment of motor function in Parkinson\u00b4s disease. Each of the 27 sub-items in the UPDRS III is measured on a scale of 0 to 4, where 0 is normal and 4 represents severe abnormalities. The total scores therefore ranges from 0 to 108.\nA negative value in Change from Baseline to Week 8 indicates an improvement in motor functions from Baseline.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Change From Baseline to the End of the Treatment Period in the Unified Parkinson\u2019s Disease Rating Scale (UPDRS) Part III (\u201con\u201d State) Total Score", 
                                    "units": "units on a scale"
                                }
                            ]
                        }, 
                        "population": "Full Analysis Set (FAS) with Last Observation Carried Forward (LOCF) as a method of imputation for missing observations. FAS includes all subjects with at least 1 patch application during Treatment Period, and with an evaluable UPDRS Part III total score at Baseline and at least 1 valid value after Baseline to Day 64.", 
                        "safety_issue": "No", 
                        "time_frame": "From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)", 
                        "title": "Change From Baseline to the End of the Treatment Period in the Unified Parkinson\u2019s Disease Rating Scale (UPDRS) Part III (\u201con\u201d State) Total Score", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "UPDRS Part II measures 'Activities in Daily Living'. The total score ranges from 0 (Best score possible) to 52 (Worst score possible).\nUPDRS Part II total score (average of \"on\" and \"off\" state) is the average of UPDRS Part II total score (\u201con\u201d state) and Part II total score (\u201coff\u201d state).\nA negative value in Change from Baseline to Week 8 indicates an improvement in activities in daily living from Baseline.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "- Titration Period: Weekly titration to the subject's optimal dose of Rotigotine between 2 mg/24 h and 8 mg/24 h. In case of intolerable Adverse Events (AEs) one back-titration is allowed during the Titration Period.\nDuration of the Titration Period: Between 1 week and 5 weeks.\n- Maintenance Period: Starts once subject reached either optimal or maximal dose of Rotigotine. Subjects receive stable dose of Rotigotine throughout the Maintenance Period. No back-titration is allowed during the Maintenance Period.\nDuration of the Maintenance Period: Between 3 weeks and 7 weeks.\nRotigotine: Application of Rotigotine up to 8 mg/24 h patches for 24 hours.", 
                                "title": "Rotigotine"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "85"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "3.8", 
                                                    "@value": "-1.5"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "UPDRS Part II measures 'Activities in Daily Living'. The total score ranges from 0 (Best score possible) to 52 (Worst score possible).\nUPDRS Part II total score (average of \"on\" and \"off\" state) is the average of UPDRS Part II total score (\u201con\u201d state) and Part II total score (\u201coff\u201d state).\nA negative value in Change from Baseline to Week 8 indicates an improvement in activities in daily living from Baseline.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Change From Baseline to the End of the Treatment Period in the Unified Parkinson\u2019s Disease Rating Scale (UPDRS) Part II (Average of \u201con\u201d and \u201cOff\u201d State) Total Score", 
                                    "units": "units on a scale"
                                }
                            ]
                        }, 
                        "population": "Full Analysis Set (FAS) with Last Observation Carried Forward (LOCF) as a method of imputation for missing observations. FAS includes all subjects with at least 1 patch application during Treatment Period, and with an evaluable UPDRS Part III total score at Baseline and at least 1 valid value after Baseline to Day 64.", 
                        "safety_issue": "No", 
                        "time_frame": "From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)", 
                        "title": "Change From Baseline to the End of the Treatment Period in the Unified Parkinson\u2019s Disease Rating Scale (UPDRS) Part II (Average of \u201con\u201d and \u201cOff\u201d State) Total Score", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Absolute time spent \"off\" is measured in hours per day. A negative value in Change from Baseline to Week 8 indicates that the time spent \"off\" decreased from Baseline and therefore indicates an improvement from Baseline.\nOnly subjects with time spent \"off\" at Baseline (subset of the Full Analysis Set (FAS)) are included in the analysis of this outcome measure.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "- Titration Period: Weekly titration to the subject's optimal dose of Rotigotine between 2 mg/24 h and 8 mg/24 h. In case of intolerable Adverse Events (AEs) one back-titration is allowed during the Titration Period.\nDuration of the Titration Period: Between 1 week and 5 weeks.\n- Maintenance Period: Starts once subject reached either optimal or maximal dose of Rotigotine. Subjects receive stable dose of Rotigotine throughout the Maintenance Period. No back-titration is allowed during the Maintenance Period.\nDuration of the Maintenance Period: Between 3 weeks and 7 weeks.\nRotigotine: Application of Rotigotine up to 8 mg/24 h patches for 24 hours.", 
                                "title": "Rotigotine"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "80"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "2.9", 
                                                    "@value": "-2.1"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Absolute time spent \"off\" is measured in hours per day. A negative value in Change from Baseline to Week 8 indicates that the time spent \"off\" decreased from Baseline and therefore indicates an improvement from Baseline.\nOnly subjects with time spent \"off\" at Baseline (subset of the Full Analysis Set (FAS)) are included in the analysis of this outcome measure.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Change From Baseline to the End of the Treatment Period in Absolute Time Spent \u201cOff\u201d", 
                                    "units": "hours/day"
                                }
                            ]
                        }, 
                        "population": "Subjects with time spent \"off\" at Baseline in the FAS with Last Observation Carried Forward (LOCF) as a method of imputation for missing observations. FAS includes all subjects with at least 1 patch application during Treatment Period, and with an evaluable UPDRS Part III total score at Baseline and at least 1 valid value after Baseline to Day 64.", 
                        "safety_issue": "No", 
                        "time_frame": "From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)", 
                        "title": "Change From Baseline to the End of the Treatment Period in Absolute Time Spent \u201cOff\u201d", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Absolute time spent \"on\" without troublesome dyskinesia is measured in hours per day. A positive value in Change from Baseline to Week 8 indicates that the time spent \"on\"  without troublesome dyskinesia increased from Baseline and therefore indicates an improvement from Baseline.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "- Titration Period: Weekly titration to the subject's optimal dose of Rotigotine between 2 mg/24 h and 8 mg/24 h. In case of intolerable Adverse Events (AEs) one back-titration is allowed during the Titration Period.\nDuration of the Titration Period: Between 1 week and 5 weeks.\n- Maintenance Period: Starts once subject reached either optimal or maximal dose of Rotigotine. Subjects receive stable dose of Rotigotine throughout the Maintenance Period. No back-titration is allowed during the Maintenance Period.\nDuration of the Maintenance Period: Between 3 weeks and 7 weeks.\nRotigotine: Application of Rotigotine up to 8 mg/24 h patches for 24 hours.", 
                                "title": "Rotigotine"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "84"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "3.1", 
                                                    "@value": "1.9"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Absolute time spent \"on\" without troublesome dyskinesia is measured in hours per day. A positive value in Change from Baseline to Week 8 indicates that the time spent \"on\"  without troublesome dyskinesia increased from Baseline and therefore indicates an improvement from Baseline.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Change From Baseline to the End of the Treatment Period in Time Spent \u201con\u201d Without Troublesome Dyskinesia", 
                                    "units": "hours/day"
                                }
                            ]
                        }, 
                        "population": "Full Analysis Set (FAS) with Last Observation Carried Forward (LOCF) as a method of imputation for missing observations. FAS includes all subjects with at least 1 patch application during Treatment Period, and with an evaluable UPDRS Part III total score at Baseline and at least 1 valid value after Baseline to Day 64.", 
                        "safety_issue": "No", 
                        "time_frame": "From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)", 
                        "title": "Change From Baseline to the End of the Treatment Period in Time Spent \u201con\u201d Without Troublesome Dyskinesia", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "The Parkinson\u00b4s Disease Sleep Scale (PDSS) is a questionnaire with 15 questions to assess sleep disturbance and nocturnal disability in Parkinson\u00b4s disease. The item- scores can range between 0= never and 4= very often. The PDSS score is a sum score of all 15 questions.\nA negative value in Change from Baseline to Week 8 indicates an improvement from Baseline.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "- Titration Period: Weekly titration to the subject's optimal dose of Rotigotine between 2 mg/24 h and 8 mg/24 h. In case of intolerable Adverse Events (AEs) one back-titration is allowed during the Titration Period.\nDuration of the Titration Period: Between 1 week and 5 weeks.\n- Maintenance Period: Starts once subject reached either optimal or maximal dose of Rotigotine. Subjects receive stable dose of Rotigotine throughout the Maintenance Period. No back-titration is allowed during the Maintenance Period.\nDuration of the Maintenance Period: Between 3 weeks and 7 weeks.\nRotigotine: Application of Rotigotine up to 8 mg/24 h patches for 24 hours.", 
                                "title": "Rotigotine"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "89"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "7.5", 
                                                    "@value": "-3.2"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The Parkinson\u00b4s Disease Sleep Scale (PDSS) is a questionnaire with 15 questions to assess sleep disturbance and nocturnal disability in Parkinson\u00b4s disease. The item- scores can range between 0= never and 4= very often. The PDSS score is a sum score of all 15 questions.\nA negative value in Change from Baseline to Week 8 indicates an improvement from Baseline.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Change From Baseline to the End of Treatment Period in Parkinson\u2019s Disease Sleep Scale 2 (PDSS-2) Total Score", 
                                    "units": "units on a scale"
                                }
                            ]
                        }, 
                        "population": "Full Analysis Set (FAS) with Last Observation Carried Forward (LOCF) as a method of imputation for missing observations. FAS includes all subjects with at least 1 patch application during Treatment Period, and with an evaluable UPDRS Part III total score at Baseline and at least 1 valid value after Baseline to Day 64.", 
                        "safety_issue": "No", 
                        "time_frame": "From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)", 
                        "title": "Change From Baseline to the End of Treatment Period in Parkinson\u2019s Disease Sleep Scale 2 (PDSS-2) Total Score", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "The Pittsburgh Sleep Quality Index (PSQI) is a questionnaire with 18 questions to assess sleep quality. The 18 questions are distributed to 7 elements with each element ranging from 0-3. The global score is the sum score of all 7 elements and ranges from 0-21 with higher values indicating worse sleep quality.\nA negative value in Change from Baseline to Week 8 indicates an improvement in sleep quality from Baseline.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "- Titration Period: Weekly titration to the subject's optimal dose of Rotigotine between 2 mg/24 h and 8 mg/24 h. In case of intolerable Adverse Events (AEs) one back-titration is allowed during the Titration Period.\nDuration of the Titration Period: Between 1 week and 5 weeks.\n- Maintenance Period: Starts once subject reached either optimal or maximal dose of Rotigotine. Subjects receive stable dose of Rotigotine throughout the Maintenance Period. No back-titration is allowed during the Maintenance Period.\nDuration of the Maintenance Period: Between 3 weeks and 7 weeks.\nRotigotine: Application of Rotigotine up to 8 mg/24 h patches for 24 hours.", 
                                "title": "Rotigotine"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "89"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "3.0", 
                                                    "@value": "-0.7"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The Pittsburgh Sleep Quality Index (PSQI) is a questionnaire with 18 questions to assess sleep quality. The 18 questions are distributed to 7 elements with each element ranging from 0-3. The global score is the sum score of all 7 elements and ranges from 0-21 with higher values indicating worse sleep quality.\nA negative value in Change from Baseline to Week 8 indicates an improvement in sleep quality from Baseline.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Change From Baseline to the End of Treatment Period in the Pittsburgh Sleep Quality Index (PSQI) Global Score", 
                                    "units": "units on a scale"
                                }
                            ]
                        }, 
                        "population": "Full Analysis Set (FAS) with Last Observation Carried Forward (LOCF) as a method of imputation for missing observations. FAS includes all subjects with at least 1 patch application during Treatment Period, and with an evaluable UPDRS Part III total score at Baseline and at least 1 valid value after Baseline to Day 64.", 
                        "safety_issue": "No", 
                        "time_frame": "From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)", 
                        "title": "Change From Baseline to the End of Treatment Period in the Pittsburgh Sleep Quality Index (PSQI) Global Score", 
                        "type": "Secondary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": {
                        "@group_id": "P1", 
                        "description": "- Titration Period: Weekly titration to the subject's optimal dose of Rotigotine between 2 mg/24 h and 8 mg/24 h. In case of intolerable Adverse Events (AEs) one back-titration is allowed during the Titration Period.\nDuration of the Titration Period: Between 1 week and 5 weeks.\n- Maintenance Period: Starts once subject reached either optimal or maximal dose of Rotigotine. Subjects receive stable dose of Rotigotine throughout the Maintenance Period. No back-titration is allowed during the Maintenance Period.\nDuration of the Maintenance Period: Between 3 weeks and 7 weeks.\nRotigotine: Application of Rotigotine up to 8 mg/24 h patches for 24 hours.", 
                        "title": "Rotigotine"
                    }
                }, 
                "period_list": {
                    "period": {
                        "drop_withdraw_reason_list": {
                            "drop_withdraw_reason": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "3", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Noncompliant"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "5", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Adverse Event"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "3", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Unable to follow protocol/ judged by inv"
                                }
                            ]
                        }, 
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "90", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "79", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "11", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }, 
                "pre_assignment_details": "Participant Flow refers to the Safety Set (SS). SS consists of all subjects who were enrolled and had at least 1 patch applied during the Treatment Period.", 
                "recruitment_details": "This multicenter study started to enroll subjects in 5 countries in October 2012."
            }, 
            "point_of_contact": {
                "name_or_title": "UCB Clinical Trial Call Center", 
                "organization": "UCB", 
                "phone": "+1 877 822 9493 (UCB)"
            }, 
            "reported_events": {
                "desc": "Adverse Events refer to the Saftey Set. Safety Set consists of all subjects who were enrolled and had at least 1 patch applied during the Treatment Period.", 
                "group_list": {
                    "group": {
                        "@group_id": "E1", 
                        "description": "- Titration Period: Weekly titration to the subject's optimal dose of Rotigotine between 2 mg/24 h and 8 mg/24 h. In case of intolerable Adverse Events (AEs) one back-titration is allowed during the Titration Period.\nDuration of the Titration Period: Between 1 week and 5 weeks.\n- Maintenance Period: Starts once subject reached either optimal or maximal dose of Rotigotine. Subjects receive stable dose of Rotigotine throughout the Maintenance Period. No back-titration is allowed during the Maintenance Period.\nDuration of the Maintenance Period: Between 3 weeks and 7 weeks.\nRotigotine: Application of Rotigotine up to 8 mg/24 h patches for 24 hours.", 
                        "title": "Rotigotine"
                    }
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "35", 
                                            "@subjects_at_risk": "90"
                                        }, 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@events": "9", 
                                            "@group_id": "E1", 
                                            "@subjects_affected": "7", 
                                            "@subjects_at_risk": "90"
                                        }, 
                                        "sub_title": "Nausea"
                                    }
                                }, 
                                "title": "Gastrointestinal disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@events": "12", 
                                            "@group_id": "E1", 
                                            "@subjects_affected": "12", 
                                            "@subjects_at_risk": "90"
                                        }, 
                                        "sub_title": "Application site pruritus"
                                    }
                                }, 
                                "title": "General disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@events": "5", 
                                            "@group_id": "E1", 
                                            "@subjects_affected": "5", 
                                            "@subjects_at_risk": "90"
                                        }, 
                                        "sub_title": "Nasopharyngitis"
                                    }
                                }, 
                                "title": "Infections and infestations"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@events": "11", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "9", 
                                                "@subjects_at_risk": "90"
                                            }, 
                                            "sub_title": "Dizziness"
                                        }, 
                                        {
                                            "counts": {
                                                "@events": "7", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "7", 
                                                "@subjects_at_risk": "90"
                                            }, 
                                            "sub_title": "Dyskinesia"
                                        }
                                    ]
                                }, 
                                "title": "Nervous system disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@events": "11", 
                                            "@group_id": "E1", 
                                            "@subjects_affected": "9", 
                                            "@subjects_at_risk": "90"
                                        }, 
                                        "sub_title": "Orthostatic hypotension"
                                    }
                                }, 
                                "title": "Vascular disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Non-systematic Assessment", 
                    "default_vocab": "MedDRA 16.0", 
                    "frequency_threshold": "5"
                }, 
                "serious_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "5", 
                                            "@subjects_at_risk": "90"
                                        }, 
                                        "sub_title": "Total, serious adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@events": "1", 
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "90"
                                        }, 
                                        "sub_title": "Subdural haemorrhage"
                                    }
                                }, 
                                "title": "Injury, poisoning and procedural complications"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@events": "1", 
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "90"
                                        }, 
                                        "sub_title": "Nasopharyngeal cancer"
                                    }
                                }, 
                                "title": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@events": "1", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "90"
                                            }, 
                                            "sub_title": "Confusional state"
                                        }, 
                                        {
                                            "counts": {
                                                "@events": "1", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "90"
                                            }, 
                                            "sub_title": "Delirium"
                                        }, 
                                        {
                                            "counts": {
                                                "@events": "1", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "90"
                                            }, 
                                            "sub_title": "Hallucination"
                                        }
                                    ]
                                }, 
                                "title": "Psychiatric disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@events": "1", 
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "90"
                                        }, 
                                        "sub_title": "Urinary retention"
                                    }
                                }, 
                                "title": "Renal and urinary disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Non-systematic Assessment", 
                    "default_vocab": "MedDRA 16.0"
                }, 
                "time_frame": "Adverse Events (AEs) were collected over the whole study duration from the Screening Period (Day -28 to Day -7) to the Safety Follow-up Visit (up to Day 78)."
            }
        }, 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Advanced Parkinson's Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is male or female, aged \u2265 30 and < 80 years at informed consent\n\n          -  Subject has idiopathic Parkinson's Disease, of more than 3 years duration, as defined\n             by the cardinal sign, bradykinesia, and the presence of at least 1 of the following:\n             resting tremor, rigidity, impairment of postural reflexes, and without any known or\n             suspected cause of Parkinsonism\n\n          -  Subject has motor fluctuations such as wearing, dyskinesia\n\n          -  Subject has experienced nocturias for at least 3 nights within 7 days prior to\n             Baseline\n\n          -  Subject is taking levodopa (L-DOPA, immediate and/or controlled release) in\n             combination with benserazide or carbidopa and has been on a stable dose of L-DOPA for\n             at least 28 days prior to Baseline (Visit 2)\n\n          -  Subject is taking a non-ergot dopamine agonist (pramipexole \u2264 1.5 mg/day or\n             ropinirole \u2264 6.0 mg/day) and has been on a stable dose of non-ergot dopamine agonist\n             for at least 28 days prior to Baseline (Visit 2)\n\n        Exclusion Criteria:\n\n          -  Subject is receiving therapy with tolcapone or budipine\n\n          -  Subject is receiving therapy with one of the following drugs either concurrently or\n             within 28 days prior to Baseline (Visit 2): alpha-methyl dopa, metoclopramide,\n             reserpine, neuroleptics (except specific atypical neuroleptics: olanzapine,\n             ziprasidone, aripiprazole, clozapine, quetiapine), monoamine oxidase A (MAO-A)\n             inhibitors, methylphenidate, or amphetamine\n\n          -  Subject has a history of symptomatic (not asymptomatic) orthostatic hypotension\n             within the 6 months prior to Baseline (Visit 2)\n\n          -  Subject has a known hypersensitivity to any components of the study medication, such\n             as a history of significant skin hypersensitivity to adhesives, known\n             hypersensitivity to other transdermal medications, or has unresolved contact\n             dermatitis\n\n          -  Subject is pregnant or nursing, or is of child-bearing potential (ie, is (i) not\n             surgically sterile, or, (ii) not using adequate birth control methods [including at\n             least one barrier method] or, (iii) not sexually abstinent, or (iv) not at least 2\n             years post menopausal)\n\n          -  Subject had a previous diagnosis of narcolepsy, sleep apnea syndrome, restless legs\n             syndrome, or periodic limb movement disorder"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 6, 2012", 
        "firstreceived_results_date": "March 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01723904", 
            "org_study_id": "PD0015"
        }, 
        "intervention": {
            "arm_group_label": "Rotigotine", 
            "description": "Application of Rotigotine up to 8 mg/24 h patches for 24 hours.", 
            "intervention_name": "Rotigotine", 
            "intervention_type": "Drug", 
            "other_name": "Neupro"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "N 0437", 
                "Pramipexol", 
                "Ropinirole"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Rotigotine", 
            "Neupro"
        ], 
        "lastchanged_date": "May 7, 2014", 
        "link": [
            {
                "description": "Product Information", 
                "url": "http://www.neupro.com/pdf/Neupro-PI.pdf"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chatswood", 
                        "country": "Australia", 
                        "state": "New South Wales"
                    }, 
                    "name": "402"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sydney", 
                        "country": "Australia", 
                        "state": "New South Wales"
                    }, 
                    "name": "401"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia", 
                        "state": "Victoria"
                    }, 
                    "name": "403"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "104"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "112"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "109"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gyeonggi-Do", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "111"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "110"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "101"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "102"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "103"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "105"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "107"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "108"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kuala Terengganu", 
                        "country": "Malaysia"
                    }, 
                    "name": "202"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kuching Sarawak", 
                        "country": "Malaysia"
                    }, 
                    "name": "204"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pulau Pinang", 
                        "country": "Malaysia"
                    }, 
                    "name": "201"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Singapore", 
                        "country": "Singapore"
                    }, 
                    "name": "501"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Singapore", 
                        "country": "Singapore"
                    }, 
                    "name": "502"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taichung", 
                        "country": "Taiwan"
                    }, 
                    "name": "302"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tainan", 
                        "country": "Taiwan"
                    }, 
                    "name": "303"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan"
                    }, 
                    "name": "306"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Australia", 
                "Korea, Republic of", 
                "Malaysia", 
                "Singapore", 
                "Taiwan"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label Study to Investigate the Safety and Efficacy of Rotigotine Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease Phase 3B", 
        "overall_official": {
            "affiliation": "+1 877 822 9493 (UCB)", 
            "last_name": "UCB Clinical Trial Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Korea: Ministry of Food and Drug Safety", 
                "Malaysia: Ministry of Health", 
                "Taiwan : Food and Drug Administration", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Singapore: Health Sciences Authority"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "The CGI Item 4 was used to assess side effects. It ranges from 0 to 4 as follows: 0 = Side effects not assessable\n= No side effects\n= Side effects do not significantly interfere with subject's functioning\n= Side effects significantly interfere with the subject's functioning\n= Side effects outweigh therapeutic efficacy.", 
                "measure": "Clinical Global Impression (CGI) Item 4 (Side Effects) at the End of the Treatment Period", 
                "safety_issue": "No", 
                "time_frame": "Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)"
            }, 
            {
                "description": "The Unified Parkinson\u00b4s Disease Rating Scale Part III is an accepted and validated scale for the assessment of motor function in Parkinson\u00b4s disease. Each of the 27 sub-items in the UPDRS III is measured on a scale of 0 to 4, where 0 is normal and 4 represents severe abnormalities. The total scores therefore ranges from 0 to 108.\nA negative value in Change from Baseline to Week 8 indicates an improvement in motor functions from Baseline.", 
                "measure": "Change From Baseline to the End of the Treatment Period in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III (\"on\" State) Total Score", 
                "safety_issue": "No", 
                "time_frame": "From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)"
            }, 
            {
                "description": "UPDRS Part II measures 'Activities in Daily Living'. The total score ranges from 0 (Best score possible) to 52 (Worst score possible).\nUPDRS Part II total score (average of \"on\" and \"off\" state) is the average of UPDRS Part II total score (\"on\" state) and Part II total score (\"off\" state).\nA negative value in Change from Baseline to Week 8 indicates an improvement in activities in daily living from Baseline.", 
                "measure": "Change From Baseline to the End of the Treatment Period in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Average of \"on\" and \"Off\" State) Total Score", 
                "safety_issue": "No", 
                "time_frame": "From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)"
            }, 
            {
                "description": "Absolute time spent \"off\" is measured in hours per day. A negative value in Change from Baseline to Week 8 indicates that the time spent \"off\" decreased from Baseline and therefore indicates an improvement from Baseline.\nOnly subjects with time spent \"off\" at Baseline (subset of the Full Analysis Set (FAS)) are included in the analysis of this outcome measure.", 
                "measure": "Change From Baseline to the End of the Treatment Period in Absolute Time Spent \"Off\"", 
                "safety_issue": "No", 
                "time_frame": "From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01723904"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Absolute time spent \"on\" without troublesome dyskinesia is measured in hours per day. A positive value in Change from Baseline to Week 8 indicates that the time spent \"on\"  without troublesome dyskinesia increased from Baseline and therefore indicates an improvement from Baseline.", 
                "measure": "Change From Baseline to the End of the Treatment Period in Time Spent \"on\" Without Troublesome Dyskinesia", 
                "safety_issue": "No", 
                "time_frame": "From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)"
            }, 
            {
                "description": "The Parkinson\u00b4s Disease Sleep Scale (PDSS) is a questionnaire with 15 questions to assess sleep disturbance and nocturnal disability in Parkinson\u00b4s disease. The item- scores can range between 0= never and 4= very often. The PDSS score is a sum score of all 15 questions.\nA negative value in Change from Baseline to Week 8 indicates an improvement from Baseline.", 
                "measure": "Change From Baseline to the End of Treatment Period in Parkinson's Disease Sleep Scale 2 (PDSS-2) Total Score", 
                "safety_issue": "No", 
                "time_frame": "From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)"
            }, 
            {
                "description": "The Pittsburgh Sleep Quality Index (PSQI) is a questionnaire with 18 questions to assess sleep quality. The 18 questions are distributed to 7 elements with each element ranging from 0-3. The global score is the sum score of all 7 elements and ranges from 0-21 with higher values indicating worse sleep quality.\nA negative value in Change from Baseline to Week 8 indicates an improvement in sleep quality from Baseline.", 
                "measure": "Change From Baseline to the End of Treatment Period in the Pittsburgh Sleep Quality Index (PSQI) Global Score", 
                "safety_issue": "No", 
                "time_frame": "From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)"
            }
        ], 
        "source": "UCB, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Otsuka Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "UCB BIOSCIENCES GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}